WeLeader Biomedical Co

WeLeader Biomedical Co Debt

The Debt of WeLeader Biomedical Co (7713.TWO) as of Oct 21, 2026 is 488.43 M TWD. In the previous year, Debt was 397.96 M TWD — a change of 22.73% (higher).

Debt

488.43 MTWD

YoY

22.73%

Last updated:

In 2025, WeLeader Biomedical Co's total debt was 488.43 M TWD, a 22.73% change from the 397.96 M TWD total debt recorded in the previous year.

The WeLeader Biomedical Co Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2020
441.21 M TWD
Jan 1, 2021
18.65 M TWD
Jan 1, 2022
270.23 M TWD
Jan 1, 2023
249.03 M TWD
Jan 1, 2024
397.96 M TWD
Jan 1, 2025
488.43 M TWD
The WeLeader Biomedical Co Debt history
YEARDebtYoY
488.43 MTWD+22.73%
397.96 MTWD+59.81%
249.03 MTWD-7.85%
270.23 MTWD+1,348.65%
18.65 MTWD-95.77%
441.21 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

WeLeader Biomedical Co Stock analysis

What does WeLeader Biomedical Co do? WeLeader Biomedical Co Ltd generates revenue through the agency and trading of in vitro diagnostic instruments and reagent-related products, primarily serving domestic markets. The company provides distribution, after-sales, and maintenance services for laboratory reagents, consumables, instruments, and equipment, alongside construction planning for medical testing laboratories. Additional services include equipment procurement, operational coaching, human resources training, and digital medical examination platforms. Domestic clients purchase these integrated solutions for healthcare facilities and laboratories. The firm's product portfolio focuses on medical testing-related services, including operational coaching and digital platform solutions, which are sold to healthcare institutions requiring comprehensive laboratory support. Distribution of in vitro diagnostic instruments and reagents forms a core revenue stream, supported by ancillary services like equipment procurement and site construction planning. These offerings target domestic healthcare providers seeking efficient laboratory management solutions. WeLeader Biomedical Co Ltd's business model combines product sales with service delivery, emphasizing domestic market penetration. The company's revenue is derived from both the sale of diagnostic instruments and reagents and the provision of specialized services such as operational coaching and digital platform access. Healthcare institutions and laboratories are the primary buyers of these integrated offerings, leveraging the company's expertise in laboratory construction and equipment maintenance. WeLeader Biomedical Co is one of the most popular companies on Eulerpool.

Debt Details

Understanding WeLeader Biomedical Co's Debt Structure

WeLeader Biomedical Co's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing WeLeader Biomedical Co's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to WeLeader Biomedical Co’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in WeLeader Biomedical Co’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about WeLeader Biomedical Co stock

Debt of WeLeader Biomedical Co is 488.43 M TWD in 2025.

Debt of WeLeader Biomedical Co changed from 397.96 M TWD to 488.43 M TWD, representing a 22.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt WeLeader Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

Debt's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's WeLeader Biomedical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — WeLeader Biomedical Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — WeLeader Biomedical Co